BioNTech SE (BNTX) Equity Average (2019)

BioNTech SE's (BNTX) quarterly Equity Average came in at $504.8 million in Q4 2019.

BioNTech SE (BNTX) Equity Average (2019) Analysis & Trends

BioNTech SE has disclosed Equity Average across 1 years of filings, most recently posting $504.8 million for Q4 2019.

Equity Average for Q4 2019 came in at $504.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $504.8 million (changed N/A YoY), and the FY2021 annual result was $7.6 billion, up 598.57% from the prior year.
Equity Average came in at $504.8 million for Q4 2019 at BioNTech SE.
In the past five years, Equity Average ranged from a high of $504.8 million in Q4 2019 to a low of $504.8 million in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Avg. (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	3.50 Bn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	783.14 Mn
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	3.76 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	1.01 Bn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	21.35 Mn
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	19.01 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	516.41 Mn
10	BioNTech SE	27.38 Bn	10.07 Bn	668.28 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	504.80 Mn